Key statistics
On Friday, AIM ImmunoTech Inc (AIM:ASQ) closed at 1.14, 10.68% above the 52 week low of 1.03 set on Feb 04, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.25 |
|---|---|
| High | 1.25 |
| Low | 1.06 |
| Bid | 1.07 |
| Offer | 1.16 |
| Previous close | 1.23 |
| Average volume | 7.07m |
|---|---|
| Shares outstanding | 2.86m |
| Free float | 2.75m |
| P/E (TTM) | -- |
| Market cap | 3.51m USD |
| EPS (TTM) | -19.82 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
More ▼
- AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
- AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
- AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering
- AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering
- AIM ImmunoTech Announces Stock Dividend
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment
- AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
- AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
- AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer
- AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
More ▼
